Skin improvement typically begins at 4–6 weeks post-infusion and progresses through 12 weeks. Plateau is reached by 3 months. Duration of remission in responders spans 3–8 months; some patients experience sustained improvement for 12+ months, whilst others require repeat infusions every 6 months. Maintenance topical therapies (emollients, vitamin D analogues) extend remission in some cohorts.
Psoriasis is a chronic autoimmune inflammatory skin disease characterised by dysregulated T-cell responses (excessive Th17 and Th1 differentiation), keratinocyte hyperproliferation, and abnormal epidermal-dermal architecture. Genetic susceptibility (HLA-Cw6 and multiple polygenic loci) interacts with environmental triggers (stress, infection, trauma) to initiate disease. Placental mesenchymal stem cells and their exosomes modulate psoriasis through multiple mechanisms: IL-17 suppression, regulatory T-cell induction (enhanced Foxp3+ Treg populations), keratinocyte proliferation restraint via TGF-β signalling, and direct anti-inflammatory cytokine secretion (IL-10, TGF-β). Eleven registered clinical trials and zero actively recruiting protocols suggest mature but limited clinical translation, with focus on moderate-to-severe, refractory disease unsuitable for conventional topical or systemic approaches.
Am I a candidate? → · Psoriasis: full overview → · Psoriasis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם